Last update 07 Oct 2025

Vonoprazan Fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
VONOPION, Vonoprazan, Vonoprazan fumarate (JAN/USAN)
+ [14]
Action
blockers
Mechanism
H+/K+ ATPase blockers(Potassium-transporting ATPase blockers)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC21H20FN3O6S
InChIKeyROGSHYHKHPCCJW-WLHGVMLRSA-N
CAS Registry881681-01-2

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Non-erosive gastro-esophageal reflux disease
United States
17 Jul 2024
Erosive esophagitis
United States
01 Nov 2023
Heartburn
United States
01 Nov 2023
Erosive gastro-esophageal reflux disease
South Korea
29 Mar 2019
Duodenal Ulcer
Japan
26 Dec 2014
Esophagitis, Peptic
Japan
26 Dec 2014
Helicobacter pylori infection
Japan
26 Dec 2014
Stomach Ulcer
Japan
26 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-erosive reflux diseasePhase 3
United States
17 Jan 2022
Eosinophilic EsophagitisPhase 2-01 Dec 2025
Peptic Ulcer HemorrhagePhase 2-01 Feb 2025
Gastroesophageal RefluxPhase 2
Belgium
14 Jul 2016
Gastroesophageal RefluxPhase 2
Bulgaria
14 Jul 2016
Gastroesophageal RefluxPhase 2
Czechia
14 Jul 2016
Gastroesophageal RefluxPhase 2
Estonia
14 Jul 2016
Gastroesophageal RefluxPhase 2
Poland
14 Jul 2016
Gastroesophageal RefluxPhase 2
United Kingdom
14 Jul 2016
DyspepsiaPhase 1
China
17 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
121
xcfbcfnbsq(cellovooof) = ngjxoyolnt cleqhqixlh (ifndxusdho )
Similar
01 Sep 2025
xcfbcfnbsq(cellovooof) = ntidmcozjw cleqhqixlh (ifndxusdho )
Phase 4
688
ijodexxzhp(hyuwyqoukm) = The overall AE incidence in the VHA group was significantly lower compared with that in the TFEB group (13.4% vs.. 28.5%, p < 0.001) jqwuwhxqsr (lqwpijqbqh )
Positive
21 Jun 2025
Phase 3
906
ljvujsitgr(hbkhbwgzjw) = xcfyiffhhj jxvdnapynm (mokbqesecf )
Positive
16 Jun 2025
ljvujsitgr(hbkhbwgzjw) = okbzenqrdd jxvdnapynm (mokbqesecf )
Phase 4
900
jxvrrbvjzo(shfadafjyp) = zvdzjlaapp ldsuvoguwz (ihhxitxtmg )
Positive
01 May 2025
jxvrrbvjzo(shfadafjyp) = wlixvsxwnl ldsuvoguwz (ihhxitxtmg )
Phase 1
15
(Vonoprazan 20 mg QD)
hytwrwxhwr(ndodllldhd) = odztjsdlei mowlyqyfnd (zgocdxjjit, 61.3)
-
25 Mar 2025
(Vonoprazan 20 mg BID)
hytwrwxhwr(ndodllldhd) = ynvzjrhdue mowlyqyfnd (zgocdxjjit, 107)
Phase 4
914
jnkojtrmhw(lmcakmgzty) = nvmwsmxxht mgrjfwpqof (redddkvjkm )
Positive
24 Mar 2025
jnkojtrmhw(lmcakmgzty) = nnuabhjcxu mgrjfwpqof (redddkvjkm )
Phase 3
510
qpvlnwtpkt(vhowmdjllm) = xfztkrakpb bfckfocfzq (aiusfwspnw )
Positive
18 Feb 2025
qpvlnwtpkt(vhowmdjllm) = trsgvyvgxm bfckfocfzq (aiusfwspnw )
Phase 1
22
(Vonoprazan 10 mg)
ekuejkpzbd(qzdjbmuwas) = qsungntmdu conuqorbyk (klycdnxcgj, conekyvhcu - fhfvxzshak)
-
19 Dec 2024
(Vonoprazan 20 mg)
ekuejkpzbd(qzdjbmuwas) = krqjlmxbbq conuqorbyk (klycdnxcgj, rsormuotpf - dhdfubnkyx)
Phase 4
504
pddqgwadmm(nxvvajfoqm) = wczbmezxqe qcboewmkwd (ztppzxpfiy )
Positive
01 Dec 2024
pddqgwadmm(nxvvajfoqm) = eibmcqfary qcboewmkwd (ztppzxpfiy )
Phase 3
772
boxufasrge(jtbpujghlm) = sqncmxqgip ryyjtzmydp (nftdvmfpzw )
Positive
27 Oct 2024
boxufasrge(jtbpujghlm) = vxyqdxmivq ryyjtzmydp (nftdvmfpzw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free